Singulex’ Cardiac Troponin Test Predicts Cardiac Risk In Stable Patients
Executive Summary
Results of from a new analysis of plasma samples from an old statin trial suggest that Singulex’ high-sensitivity cardiac troponin test can track the cardiovascular risk in stable patients with ischemic heart disease.
You may also be interested in...
Singulex: Next-Gen Immunodiagnostics
Singulex originally developed its Single Molecule Counting technology for research applications, but it is poised to launch a clinical diagnostics tool that incorporates the highly sensitive technology.
High-Dose Statins IDEAL For Use In High-Risk Patients, Study Suggests
Results of the IDEAL study support the aggressive use of high-dose statins as standard therapy for patients at high risk of repeat cardiovascular events, Scott Grundy (University of Texas Southwestern Medical Center) told the American Heart Association annual meeting Nov. 15 in Dallas
Medtronic Earns CE Mark For Affera Ablation System, Touts New PFA Results
Results of the PULSED AF trial confirm that Medtronic’s PulseSelect pulsed field ablation is safe and effective for atrial fibrillation ablation. The company will likely incorporate PulseSelect into its Affera cardiac mapping and ablation system, which will soon be available in Europe.